The JAK inhibitor baricitinib inhibits oncostatin M induction of proinflammatory mediators in ex-vivo synovial derived cells
Sam Weston(Nuffield Orthopaedic Centre), Peter C. Taylor(Nuffield Orthopaedic Centre)
Cited by 16
Related Papers
A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19
|Advances in Therapy|2022|58
Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
|Advances in Therapy|2023|38
Inflammatory disease microbiomes share a functional pathogenicity predicted by C-reactive protein
|bioRxiv (Cold Spring Harbor Laboratory)|2025|0